StreetInsider.com News Articles

Form SCHEDULE 13G PAVmed Inc. Filed by: Two Seas Capital LP

Fri, 15 May 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26508109.html

Form SCHEDULE 13G PAVmed Inc. Filed by: Two Seas Capital LP

Fri, 15 May 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26508109.html

Form 8-K PAVmed Inc. For: May 15

Fri, 15 May 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26499851.html

Form 8-K PAVmed Inc. For: May 15

Fri, 15 May 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26499851.html

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones

PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing

Conference call and webcast to be held today, May 15, at 8:30 AM EDT

NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating

Form 10-Q PAVmed Inc. For: Mar 31

Thu, 14 May 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260514/26496688.html

Form 10-Q PAVmed Inc. For: Mar 31

Thu, 14 May 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260514/26496688.html

Form SCHEDULE 13G PAVmed Inc. Filed by: FIRST MANHATTAN CO. LLC.

Thu, 14 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260514/26495852.html

Form SCHEDULE 13G PAVmed Inc. Filed by: FIRST MANHATTAN CO. LLC.

Thu, 14 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260514/26495852.html

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Thu, 14 May 2026 08:00:00 -0400

Processed 3,177 EsoGuard^® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones

Conference call and webcast to be held today, May 14, at 8:30 AM EDT

NEW YORK, May 14, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company